EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

Inclusion Criteria: * Age \> 21 years and \< 65 years - male or female * Overweight or obese individuals (BMI ≥ 27 kg/m2 and ≤ 40 kg/m2) * Diagnosed with Type 2 diabetes and being treated by diet or oral agents (metformin, SU, DPP-4i, or TZD) * Glycemic state: HbA1c at screening 7.0-10.0%. * History of failure with non-surgical weight loss methods * Subjects willing to comply with study requirements * Subjects who have signed an informed consent form Exclusion Criteria: Diabetic subjects requiring injectable treatments (insulin, GLP-1R agonists) * Subjects requiring anticoagulation therapy * Subjects with iron deficiency and iron deficiency anemia * Condition of the gastrointestinal tract, such as ulcers or inflammatory bowel disease * Treatment represents an unreasonable risk to the subject * Known history of acute or chronic pancreatitis * Known history of organ failure (i.e. renal insufficiency, heart failure, fibrotic / cirrhotic liver disease, or pulmonary disease) * Symptomatic coronary artery disease or pulmonary dysfunction * Subjects with known symptomatic biliary disease * Known infection at the time of implant * Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia * Congenital or acquired anomalies of the GI tract such as atresias or stenoses * Pregnant or has the intention of becoming pregnant in the next 6 months * Unresolved alcohol or drug addiction * HIV positive subjects * Subjects with hepatitis B or C * Currently taking the following medications within 30 days of implant: systemic corticosteroids, drugs known to affect GI motility, prescription or over the counter weight loss medications such as Sibutramine hydrochloride monohydrate and Orlistat * Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all equivalent antibiotics * Any characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement in this clinical trial * Previous GI surgery that could affect the ability to place the liner or the function of the implant. * Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period * H. pylori positive subjects (Note: patients may be enrolled if they had a prior history and were successfully treated). * Family or subject history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder * Unable to tolerate proton pump inhibitors * Participating in another ongoing investigational clinical trial that is ongoing or within 3 months of the implant date * Positive stool guaiac at time of screening